Paradigm Biopharmaceuticals Ltd (ASX:PAR) Chief Medical Officer and Interim CEO Dr. Donna Skerrett tells Proactive the Melbourne, Australia-based clinical stage biopharmaceutical company has been granted Fast Track Designation for the company’s phase 3 program to treat osteoarthritis.
Dr. Skerett says this will provide opportunity for shorter review timelines for the group, which is focused on repurposing existing drugs for new indications.